Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 8.95B +253.8% |
| Revenue (ttm) | 42.16M +2,928.4% |
| Net Income | -501.61M |
| EPS | -5.03 |
| Shares Out | 106.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,229,695 |
| Open | 84.25 |
| Previous Close | 84.15 |
| Day's Range | 84.20 - 84.37 |
| 52-Week Range | 26.50 - 84.37 |
| Beta | 0.09 |
| Analysts | Hold |
| Price Target | 85.50 (+1.38%) |
| Earnings Date | Aug 3, 2026 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida... [Read more]
Financial Performance
In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for CRNX stock is "Hold." The 12-month stock price target is $85.5, which is an increase of 1.38% from the latest price.
News
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired
Crinetics Pharmaceuticals Earnings release: Q2 2026
Crinetics Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Crinetics Pharmaceuticals Quarterly report: Q2 2026
Crinetics Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics downgraded to Neutral from Buy at UBS
UBS downgraded Crinetics (CRNX) to Neutral from Buy with an $85 price target after Vertex Pharmaceuticals (VRTX) agreed to acquire the company for $85 per share in cash. Published first…
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 21, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics Pharmaceuticals Slides: Corporate presentation
Crinetics Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on July 10, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics downgraded to Hold from Buy at Stifel
Stifel analyst Alex Thompson downgraded Crinetics (CRNX) to Hold from Buy with a price target of $85, up from $83, after Vertex Pharmaceuticals (VRTX) agreed to acquire the company for…
How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks
More mergers among brand-name consumer companies seem likely—following a record $2.6 trillion worth of transactions announced in the first half of 2026.
Crinetics downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Crinetics (CRNX) to In Line from Outperform with a price target of $85, down from $88, after Vertex Pharmaceuticals (VRTX) agreed to acquire the company for $85…
Crinetics downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Tyler Van Buren downgraded Crinetics (CRNX) to Hold from Buy with no price target after Vertex Pharmaceuticals (VRTX) announced an agreement to acquire the the company for…
Crinetics downgraded to Market Perform from Outperform at Citizens
Citizens analyst Jonathan Wolleben downgraded Crinetics (CRNX) to Market Perform from Outperform after Vertex Pharmaceuticals (VRTX) agreed to acquire the company for $85 per share in cash. Published ...
Crinetics downgraded to Hold from Buy at Jefferies
Jefferies downgraded Crinetics (CRNX) to Hold from Buy with a price target of $85, up from $55, after the company announced it will be acquired by Vertex Pharmaceuticals (VRTX) for…
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
Wedbush notes that Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85/share in cash. Crinetics now trades essentially at the deal price, reflecting high confidenc...
Crinetics shares surge after Vertex agrees to $10B cash buyout
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-...
Crinetics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Crinetics (CRNX) to Hold from Buy with an $85 price target after Vertex Pharmaceuticals (VRTX) agreed to acquire the company for $85 per share in cash. Published first…
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceutica...
Crinetics downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi downgraded Crinetics (CRNX) to Neutral from Overweight after Vertex Pharmaceuticals (VRTX) agreed to acquire the company for $85 per share in cash. Published first...
Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright
After Vertex Pharmaceuticals’ (VRTX) announcement of an agreement to acquire Crinetics (CRNX) for $85 per share in cash, H.C. Wainwright analyst Andrew Fein thinks “the most important question” is wha...
Crinetics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Crinetics (CRNX) to Neutral from Buy with an $85 price target following Vertex Pharmaceuticals’ (VRTX) announcement of an agreement to acquire the company for $85 per share…
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.